The modern biopharmaceutical industry is witnessing a significant transformation, thanks to the integration of artificial intelligence (AI) tools in early drug discovery. AI’s capabilities in managing and analyzing vast amounts of data generated from cell-based preclinical models through imaging
In a significant leap forward for oncology, the U.S. Food and Drug Administration (FDA) has given the green light to Astellas Pharma Inc.'s VYLOY (zolbetuximab-clzb) for treating adults with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or
Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The
Respiratory syncytial virus (RSV) has long been a formidable challenge, particularly for infants and older adults. Characterized by cold-like symptoms, RSV can sometimes escalate into severe respiratory conditions necessitating hospitalization. Nearly every child is exposed to RSV by the age of
Gilead Sciences recently announced its decision to withdraw Trodelvy from the market as a treatment for bladder cancer, following disappointing results from its confirmatory TROPiCS-04 clinical trial. This marks a notable shift for a drug that initially showed promise in shrinking tumors and
AbbVie, renowned for its portfolio of groundbreaking treatments, has achieved a major milestone with the FDA's approval of Vyalev, a novel combination therapy aimed at providing extended movement control for patients with advanced Parkinson’s disease. The approval represents more than just a
